Oyster Point Pharma Inc (OQ:OYST)

Business Focus: Biotechnology & Medical Research

Latest 10 SEC filings (by transaction date) for OYST within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET November 12th, 2019
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Nov 5/19 Nov 5/19 Kerins Patrick J Indirect Ownership Common Stock, par value $0.001 per share Form 3 : Initial Statement of Beneficial Ownership of Securities    
Nov 4/19 Nov 4/19 New Enterprise Associates 14, L.P. Direct Ownership Series B Convertible Preferred Stock C - Conversion -1,061,547  
Nov 4/19 Nov 4/19 New Enterprise Associates 14, L.P. Direct Ownership Series A Convertible Preferred Stock C - Conversion -3,606,282  
Nov 4/19 Nov 4/19 New Enterprise Associates 14, L.P. Direct Ownership Common Stock, par value $0.001 per share P - Open market or private purchase 935,000 $16.00
Nov 4/19 Nov 4/19 New Enterprise Associates 14, L.P. Direct Ownership Common Stock, par value $0.001 per share C - Conversion 1,061,547  
Nov 4/19 Nov 4/19 New Enterprise Associates 14, L.P. Direct Ownership Common Stock, par value $0.001 per share C - Conversion 3,606,282  
Nov 4/19 Nov 4/19 Falcon Vision LLC Indirect Ownership Series B Convertible Preferred Stock C - Conversion -884,622  
Nov 4/19 Nov 4/19 Falcon Vision LLC Indirect Ownership Common Stock, par value $0.001 per share P - Open market or private purchase 155,000 $16.00
Nov 4/19 Nov 4/19 Falcon Vision LLC Indirect Ownership Common Stock, par value $0.001 per share C - Conversion 884,622  
Nov 4/19 Nov 4/19 KKR Fund Holdings L.P. Indirect Ownership Series B Convertible Preferred Stock C - Conversion -884,622  
Sign up or login above to see all SEC filings within the past 6 months.
Latest 10 SEC filings (by filing date) for OYST within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET November 12th, 2019
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Nov 6/19 Nov 4/19 InvOpps GP IV, L.L.C. Indirect Ownership Series B Convertible Preferred Stock C - Conversion -1,230,050  
Nov 6/19 Nov 4/19 InvOpps GP IV, L.L.C. Indirect Ownership Series B Convertible Preferred Stock C - Conversion -609,965  
Nov 6/19 Nov 4/19 InvOpps GP IV, L.L.C. Indirect Ownership Common Stock, par value $0.001 per share P - Open market or private purchase 501,375 $16.00
Nov 6/19 Nov 4/19 InvOpps GP IV, L.L.C. Indirect Ownership Common Stock, par value $0.001 per share P - Open market or private purchase 248,625 $16.00
Nov 6/19 Nov 4/19 InvOpps GP IV, L.L.C. Indirect Ownership Common Stock, par value $0.001 per share C - Conversion 1,230,050  
Nov 6/19 Nov 4/19 InvOpps GP IV, L.L.C. Indirect Ownership Common Stock, par value $0.001 per share C - Conversion 609,965  
Nov 5/19 Nov 5/19 Kerins Patrick J Indirect Ownership Common Stock, par value $0.001 per share Form 3 : Initial Statement of Beneficial Ownership of Securities    
Nov 5/19 Nov 4/19 Snisarenko John Direct Ownership Common Stock, par value $0.001 per share P - Open market or private purchase 3,000 $16.00
Nov 5/19 Nov 4/19 Lochner Daniel Direct Ownership Common Stock, par value $0.001 per share P - Open market or private purchase 6,300 $16.00
Nov 5/19 Nov 4/19 Oyster Point Pharma I, Llc Direct Ownership Series B Convertible Preferred Stock C - Conversion -955,392  
Sign up or login above to see all SEC filings within the past 6 months.
Sign up or login above to see the past 6 months of filings sorted by insider. .
Get holdings trends & enhanced insider charts in PDF now
Comment On!
140

Twitter

Search (past week) for $OYST

StockTwits